All In Biotech

Drug Trial Radar · NCT00185393

Treatment With [90]Y-Ibritumomab Tiuxetan Versus no Treatment in Patients With Follicular Non Hodgkin Lymphoma (Stage III or IV) Having Achieved a Partial or Complete Remission After First Line Chemotherapy

Efficacy and Safety of Subsequent Treatment With [90]Y-Ibritumomab Tiuxetan Versus no Further Treatment in Patients With Stage III or IV Follicular Non-Hodgkin's Lymphoma Having Achieved Partial or Complete Remission After First Line Chemotherapy. A Prospective, Multicenter, Randomized Phase III Clinical Trial

Last checked: Nov 20, 2026Latest source record: Dec 1, 2008 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 414 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

414

Actual

Start

Aug 2001

Primary completion

Not stated

Study completion Feb 2007

Sponsor

Lead sponsor
BayerBayer (BAYRY)
Sponsor type
Industry
First posted
Sep 16, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The aim of the study is to test \[90\]Y-ibritumomab tiuxetan, a radioactive antibody, in patients with stage III or IV follicular lymphoma whose disease is in partial or complete remission after first line chemotherapy. The radioactive antibody will be compared with no further treatment to see which is better in the long term after standard lymphoma treatment.

Conditions

  • Lymphoma, Non-Hodgkin

Interventions

  • Zevalin ([90]Y-ibritumomab tiuxetan, BAY86-5128)Biological

    treatment with 90 Yttrium-labeled anti CD 20 antibody

  • no treatmentOther

    no treatment

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression free survivalTime frame: End of study

Locations

95 sites in 13 countries. Site status is shown where the registry gives one.

  • Site not named

    Antwerp, Belgium

  • Site not named

    Bruges, Belgium

  • Site not named

    Brussels, Belgium

  • Site not named

    Ghent, Belgium

  • Site not named

    Leuven, Belgium

  • Site not named

    Yvoir, Belgium

  • Site not named

    Edmonton, Alberta, Canada

  • Site not named

    Vancouver, British Columbia, Canada

  • Site not named

    Hamilton, Ontario, Canada

  • Site not named

    Ottawa, Ontario, Canada

  • Site not named

    Toronto, Ontario, Canada

  • Site not named

    Toronto, Ontario, Canada

  • Site not named

    Montreal, Quebec, Canada

  • Site not named

    Montreal, Quebec, Canada

  • Site not named

    Aarhus, Denmark

  • Site not named

    Copenhagen, Denmark

  • Site not named

    Angers, France

  • Site not named

    Besançon, France

  • Site not named

    Bordeaux, France

  • Site not named

    Créteil, France

  • Site not named

    Grenoble, France

  • Site not named

    Le Mans, France

  • Site not named

    Lille, France

  • Site not named

    Lyon, France

  • Site not named

    Paris, France

  • Site not named

    Pierre-Bénite, France

  • Site not named

    Rouen, France

  • Site not named

    Strasbourg, France

  • Site not named

    Tours, France

  • Site not named

    Rennes, Brittany Region, France

  • Site not named

    Hamburg, Germany

  • Site not named

    Tübingen, Baden-Wurttemberg, Germany

  • Site not named

    Augsburg, Bavaria, Germany

  • Site not named

    München, Bavaria, Germany

  • Site not named

    Göttingen, Lower Saxony, Germany

  • Site not named

    Münster, Nordrhein-Westfalen / 298, Germany

  • Site not named

    Hamm, Nordrhein-Westfalen / 358, Germany

  • Site not named

    Cologne, North Rhine-Westphalia, Germany

  • Site not named

    Düsseldorf, North Rhine-Westphalia, Germany

  • Site not named

    Dresden, Saxony, Germany

Showing 40 of 95 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.